Today's data selection: Kanu is gradually approaching the coastal areas of Zhejiang and Fujian; How to do well in personal health protection after rainstorm and flood | Organization | rainstorm
Kanu is gradually approaching the coastal areas of Zhejiang and Fujian
The center of Typhoon Kanu, the 6th typhoon of this year, was located at 11:00 am on August 2 in the East China Sea, about 570 kilometers southeast of Yuhuan City, Zhejiang Province. The maximum wind force near the center was 16 levels, and it is expected that Kanu will move westward at a speed of 10-15 kilometers per hour, with little change in intensity, and will approach the coastal areas from central Zhejiang to northern Fujian. According to the Emergency Plan for Flood Control, Typhoon Prevention, and Drought Relief in Zhejiang Province, the Zhejiang Provincial Flood Control Index raised the emergency response for typhoon prevention to level three on the 2nd.
How to do well in personal health protection after rainstorm and flood
Reminder from the National Bureau of Disease Control and Prevention: ① Do not drink raw water; ② Do not eat spoiled food; ③ Avoid soaking hands and feet in water for a long time; ④ Wash hands frequently and do not share personal hygiene products; ⑤ If there is diarrhea or rash after flooding, seek medical attention as soon as possible
Northeast China may experience prolonged rainfall
According to the Central Meteorological Observatory, in the coming days, the focus of rainfall in the north will shift to the northeast region. Some regions, such as eastern Inner Mongolia, eastern and southern Heilongjiang, western and northern Jilin, central and southern Yunnan, central and western Hainan Island, northern Taiwan Island, etc., have heavy to rainstorm, while some local regions, such as southeastern Heilongjiang, northern Jilin, etc., have heavy rainstorm. The northeast region has a long rainfall period, and local or severe convection weather is accompanied, so precautions should be taken.
July box office breaks a new record in film history
In the just past July, the total box office revenue was 8.717 billion yuan, setting a new record in Chinese film history for July box office, breaking the record for monthly box office except for the Spring Festival season, and entering the top six of the Chinese film history single month box office chart.
According to data from Cat's Eye Professional Edition, as of 3:00 pm on August 1, the total box office for the 2023 summer season has also skyrocketed with the box office in July, exceeding 13 billion yuan; As of 24:00 on July 31, the total box office of films in 2023 has also exceeded 35 billion yuan, while the total box office of films in China in 2022 was 30.067 billion yuan.
The Daily Economic News reporter noticed that as early as early June, the industry's estimated summer box office was still between 12 and 13 billion yuan, while the figure of 15 billion yuan was considered "expected to hit". At present, achieving this goal seems to be a definite certainty, and the highest grossing summer box office in Chinese film history is 17.778 billion yuan.
US institutions claim to have developed drugs that can kill all solid cancer tumors
The top cancer treatment and research institution in the United States, Hope City National Medical Center, announced on Tuesday that in preclinical studies, its scientists have developed a targeted chemotherapy drug that can kill all solid malignant tumors.
The preclinical studies mentioned in the announcement have been published in the form of papers in the Journal of Cellular Chemical Biology. The drug mentioned earlier is an oral small molecule PCNA inhibitor used to inhibit tumor cell proliferation.
Dr. Linda Malkas, who developed this drug, introduced that PCNA is like an aviation hub containing multiple aircraft terminals. This cancer killer pill is like a blizzard shutting down key aviation hubs, grounding only planes carrying cancer cells. With the validation of drug feasibility through animal models, AOH1996 has also entered the Phase I clinical trial stage, which mainly tests the safety and recommended dosage of the drug.